The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
Abstract
An increased risk of cancer has been reported in patients treated with azathioprine. To assess the long-term risk of neoplasia in azathioprine-treated multiple sclerosis (MS) patients, we conducted a case-control study using the Lyon Multiple Sclerosis Database. From the 1,191 MS patients included in the database, we identified patients who developed cancer before December 31, 1991. Each case was then matched to three cancer-free MS controls by gender, date of birth, and date of MS onset. A matched analysis was performed to compare cases and controls for exposure to azathioprine therapy during the same follow-up period. Twenty-three MS patients with cancer were identified: 17 solid tumors, 2 skin carcinomas, 4 hematopoietic cancers. Cases had a mean age of 34.5 years +/- 10.2 (+/- SD) at clinical onset of MS and have been followed up for an average 13.8 years +/- 8.1 before being diagnosed with cancer. Fourteen cases (61%) and 34 controls (49%) had been treated with azathioprine for at least 1 month after being diagnosed with MS (adjusted odds ratio = 1.7; 95% confidence interval [CI], 0.6 to 4.6). When assessing risk associated with different durations of azathioprine therapy compared with no treatment at all, we found that MS patients had an increase in cancer risk of 1.3 (95% CI, 0.4 to 4.0) when treated less than 5 years, of 2.0 (95% CI, 0.4 to 9.1) when treated 5 to 10 years, and of 4.4 (95% CI 0.9 to 20.9) when treated more than 10 years. Similar results were obtained when assessing cancer risk associated with cumulative doses of azathioprine ever taken. This case-control study suggests that the overall long-term risk of cancer from azathioprine is low in MS patients. The results are suggestive of a dose-response relationship with no significant risk during the first years of treatment and a possible increased risk after about 10 years of continuous therapy. Further studies are needed to better assess the risk-benefit ratio of azathioprine in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grantham-McGregor, S. M., Powell, C. A., Walker, S. P., & Himes, J. H. (1991) · The Lancet · doi:10.1016/0140-6736(91)90001-6 · Cited by 685
An introduction to the free radical hypothesis in Parkinson's disease
Olanow, C. W. (1992) · Annals of Neurology · doi:10.1002/ana.410320703 · Cited by 382
Cited by
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Dantal, J., Hourmant, M., Cantarovich, D., Giral, M., Blancho, G., Dreno, B., & Soulillou, J.-P. (1998) · The Lancet · doi:10.1016/s0140-6736(97)08496-1 · Cited by 745
Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management
Berg, D., & Otley, C. C. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.125579 · Cited by 723
Vaccinations and the Risk of Relapse in Multiple Sclerosis
Confavreux, C., Suissa, S., Saddier, P., Bourdès, V., & Vukusic, S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102013440501 · Cited by 490
Self-citation
Metadata
- Authors
- Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P., & Aimard, G.
- Venue
- Neurology
- Published
- 1996-06
- Volume
- 46
- Issue
- 6
- Pages
- 1607-1612
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2009680091
- Cited by
- 203
- References
- 2
- FWCI
- 8.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. https://app.cochat.ai/papers/10.1212/wnl.46.6.1607
- The paper
- Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P., & Aimard, G. (1996). Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology. https://doi.org/10.1212/wnl.46.6.1607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.